Faes Farma SA (FAE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Faes Farma SA (FAE) has a cash flow conversion efficiency ratio of 0.056x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€43.90 Million ≈ $51.32 Million USD) by net assets (€777.46 Million ≈ $908.93 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see FAE market cap overview for the company's overall valuation and market capitalisation.
Faes Farma SA - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how Faes Farma SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Faes Farma SA (FAE) stock price for real-time trading data and today's change.
Faes Farma SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Faes Farma SA ranked by their cash flow conversion efficiency. Review FAE cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
World Kinect Corporation
NYSE:WKC
|
-0.038x |
|
Boston Beer Company Inc
NYSE:SAM
|
0.112x |
|
Natural Resource Partners LP
NYSE:NRP
|
0.052x |
|
Linea Directa Aseguradora SA Compania de Seguros y Reaseguros
MC:LDA
|
0.182x |
|
Hillman Solutions Corp
NASDAQ:HLMN
|
0.087x |
|
Pci-Suntek Technology Co Ltd
SHG:600728
|
0.008x |
|
Golden Ocean Group Limited
F:KT31
|
-0.002x |
|
PC Jeweller Limited
NSE:PCJEWELLER
|
0.004x |
Annual Cash Flow Conversion Efficiency for Faes Farma SA (2005–2025)
The table below shows the annual cash flow conversion efficiency of Faes Farma SA from 2005 to 2025. Also see Faes Farma SA balance sheet assets for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €747.70 Million ≈ $874.14 Million |
€78.49 Million ≈ $91.76 Million |
0.105x | -33.94% |
| 2024-12-31 | €726.62 Million ≈ $849.49 Million |
€115.47 Million ≈ $134.99 Million |
0.159x | +4.40% |
| 2023-12-31 | €663.35 Million ≈ $775.52 Million |
€100.97 Million ≈ $118.04 Million |
0.152x | -14.15% |
| 2022-12-31 | €602.28 Million ≈ $704.13 Million |
€106.79 Million ≈ $124.85 Million |
0.177x | +19.78% |
| 2021-12-31 | €538.07 Million ≈ $629.06 Million |
€79.64 Million ≈ $93.11 Million |
0.148x | -10.82% |
| 2020-12-31 | €472.88 Million ≈ $552.84 Million |
€78.49 Million ≈ $91.76 Million |
0.166x | +1.59% |
| 2019-12-31 | €413.65 Million ≈ $483.60 Million |
€67.58 Million ≈ $79.01 Million |
0.163x | -0.83% |
| 2018-12-31 | €360.15 Million ≈ $421.06 Million |
€59.34 Million ≈ $69.37 Million |
0.165x | +26.65% |
| 2017-12-31 | €320.77 Million ≈ $375.02 Million |
€41.73 Million ≈ $48.78 Million |
0.130x | -25.32% |
| 2016-12-31 | €284.89 Million ≈ $333.06 Million |
€49.62 Million ≈ $58.02 Million |
0.174x | +8.29% |
| 2015-12-31 | €254.34 Million ≈ $297.34 Million |
€40.91 Million ≈ $47.83 Million |
0.161x | +14.00% |
| 2014-12-31 | €228.63 Million ≈ $267.29 Million |
€32.26 Million ≈ $37.71 Million |
0.141x | -11.81% |
| 2013-12-31 | €197.81 Million ≈ $231.26 Million |
€31.65 Million ≈ $37.00 Million |
0.160x | +23.86% |
| 2012-12-31 | €184.82 Million ≈ $216.07 Million |
€23.87 Million ≈ $27.91 Million |
0.129x | +8.38% |
| 2011-12-31 | €167.61 Million ≈ $195.96 Million |
€19.98 Million ≈ $23.35 Million |
0.119x | +29.44% |
| 2010-12-31 | €165.51 Million ≈ $193.50 Million |
€15.24 Million ≈ $17.81 Million |
0.092x | -33.21% |
| 2009-12-31 | €122.93 Million ≈ $143.71 Million |
€16.95 Million ≈ $19.81 Million |
0.138x | -37.03% |
| 2008-12-31 | €156.71 Million ≈ $183.21 Million |
€34.31 Million ≈ $40.11 Million |
0.219x | +153.53% |
| 2007-12-31 | €151.06 Million ≈ $176.60 Million |
€13.04 Million ≈ $15.25 Million |
0.086x | -39.41% |
| 2006-12-31 | €139.85 Million ≈ $163.50 Million |
€19.93 Million ≈ $23.30 Million |
0.143x | +40.54% |
| 2005-12-31 | €131.62 Million ≈ $153.88 Million |
€13.35 Million ≈ $15.60 Million |
0.101x | -- |
About Faes Farma SA
Faes Farma, S.A., researches, develops, produces, and markets pharmaceutical products, healthcare products, and raw materials internationally. The company operates through Pharmaceutical and Healthcare Specialties; Animal Nutrition and Health; and Pharmaceutical Raw Materials segments. It engages in chemical and pharmaceutical products, foodstuffs, cosmetics, dietetics and medicinal plants servic… Read more